Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva®) and Gefitinib (Iressa®)

Fantl, 1993, Signalling by receptor tyrosine kinases, Annu Rev Biochem, 62, 453, 10.1146/annurev.bi.62.070193.002321

Brabender, 2001, Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival, Clin Cancer Res, 7, 1850

Rubin Grandis, 1998, Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival, J Natl Cancer Inst, 90, 824, 10.1093/jnci/90.11.824

Baselga, 2000, New technologies in epidermal growth factor receptor-targeted cancer therapy, Signal, 1, 12

Woodburn, 1999, The epidermal growth factor receptor and its inhibition in cancer therapy, Pharmacol Ther, 82, 241, 10.1016/S0163-7258(98)00045-X

Meyers, 1988, Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells, J Cell Biochem, 38, 87, 10.1002/jcb.240380203

Ritter, 2003, The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors, Semin Oncol, 30, 3, 10.1053/sonc.2003.50027

Baselga, 2002, Why the epidermal growth factor receptor? The rationale for cancer therapy, The Oncologist, 7, 2, 10.1634/theoncologist.7-suppl_4-2

Brehmer, 2005, Cellular targets of gefitinib, Cancer Res, 65, 379, 10.1158/0008-5472.379.65.2

Ranson, 2002, ZD1839 (Iressa™): for more than just non-small cell lung cancer, The Oncologist, 7, 16, 10.1634/theoncologist.7-suppl_4-16

Herbst, 2002, Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small cell lung cancer and other solid tumors: results of a phase I trial, J Clin Oncol, 20, 3815, 10.1200/JCO.2002.03.038

Giaccone, 2005, Her1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy, Ann Oncol, 16, 538, 10.1093/annonc/mdi129

Giaccone, 2004, Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1, J Clin Oncol, 22, 777, 10.1200/JCO.2004.08.001

Herbst, 2004, Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2, J Clin Oncol, 22, 785, 10.1200/JCO.2004.07.215

Gatzemeier, 2004, Results of a phase II trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC), Proc Am Soc Clin Oncol, 22, 7010, 10.1200/jco.2004.22.90140.7010

Herbst, 2004, TRIBUTE—a phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC), Proc Am Soc Clin Oncol, 22, 7011, 10.1200/jco.2004.22.90140.7011

Friedmann, 2004, Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839), Clin Cancer Res, 10, 6476, 10.1158/1078-0432.CCR-04-0586

Akita, 2003, Preclinical studies with erlotinib (Tarceva), Semin Oncol, 30, 15, 10.1016/S0093-7754(03)70011-6

Fukuoka, 2002, Final results from a phase II trial of ZD1839 (‘Iressa’) for patients with advanced non-small-cell lung cancer (IDEAL1), Proc Am Soc Clin Oncol, 21, 298a

Kris, 2002, A phase II trial of ZD1839 (‘Iressa’) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL2), Proc Am Soc Clin Oncol, 21, 292a

Perez-Soler, 2003, Final results of a phase II study of erlotinib (Tarceva) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum based chemotherapy, Lung Cancer, 41, S246, 10.1016/S0169-5002(03)92578-5

Perez-Soler, 2004, Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer, Clin Lung Cancer, 6, S20, 10.3816/CLC.2004.s.010

Patel, 2003, Encouraging activity and durable responses demonstrated by the EGFR tyrosine kinase inhibitor erlotinib (Tarceva, OSI-774) in patients with advanced bronchoalveolar (BAC) cell carcinoma, Lung Cancer, 41, S56, 10.1016/S0169-5002(03)91846-0

West, 2003, ZD1839 (Iressa) in advanced bronchoalveolar carcinoma (BAC): a preliminary report of SWOG S0126, Lung Cancer, 41, S56, 10.1016/S0169-5002(03)91845-9

Twombly, 2005, Failing survival advantage in crucial trial, future of Iressa in jeopardy, J Natl Cancer Inst, 97, 249, 10.1093/jnci/97.4.249

Fuster, 2004, Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes, Clin Lung Cancer, 6, S24, 10.3816/CLC.2004.s.011

Albanell, 2002, Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition, J Clin Oncol, 20, 110, 10.1200/JCO.2002.20.1.110

Mohamed, 2005, Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer, Ann Oncol, 16, 780, 10.1093/annonc/mdi157

Knezevic, 2004, Development of a HER1 assay using individual human hair follicles, Proc Am Soc Clin Oncol, 23, 3044, 10.1200/jco.2004.22.90140.3044

Baselga, 2002, Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types, J Clin Oncol, 20, 4292, 10.1200/JCO.2002.03.100

Soulieres, 2003, Identifying predictive and surrogate markers of erlotinib anti-tumor activity other than rash, Oncology (Williston Park), 17, 29

Hirsch, 2005, Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer, Curr Opin Oncol, 17, 118, 10.1097/01.cco.0000155059.39733.9d

Pao, 2005, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib and erlotinib, PLoS Med, 2, 57

Kelly, 2000, ZD1839 (Iressa), an oral EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor): pharmacokinetic results of a phase I study in patients with advanced cancer, Proc Am Assoc Cancer Res, 41, 612

Kris, 1999, Phase I study of oral ZD1839 (Iressa), a novel inhibitor of epidermal growth factor tyrosine kinase (EGFR-TK): evidence of good tolerability and activity, Clin Cancer Res, 5, 3749s

Sandler, 2003, Clinical experience with HER1/EGFR tyrosine kinase inhibitor erlotinib, Oncology (Williston Park), 17, 17

2004, U.S. Food and Drug Administration. Tarceva® (erlotinib tablets), 1

Hidalgo, 2001, Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies, J Clin Oncol, 19, 3267, 10.1200/JCO.2001.19.13.3267

2003, U.S. Food and Drug Administration. Iressa® (gefitinib tablets), 1

Ciardiello, 2001, A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor, Clin Cancer Res, 7, 2958

Camus, 2001, Drug-induced infiltrative lung disease, Eur Respir J Suppl, 32, 93s

McCune, 2000, In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone, Clin Pharmacol Ther, 68, 356, 10.1067/mcp.2000.110215

Wakeling, 2002, ZD1839 (Iressa®): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy, Cancer Res, 62, 5749

Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, 350, 2129, 10.1056/NEJMoa040938

Bardelli, 2003, Mutational analysis of the tyrosine kinome in colorectal cancers, Science, 300, 949, 10.1126/science.1082596

Pao, 2004, EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib, Proc Natl Acad Sci U S A, 101, 13306, 10.1073/pnas.0405220101

Shigematsu, 2005, Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers, J Natl Cancer Inst, 97, 339, 10.1093/jnci/dji055

Sordella, 2004, Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways, Science, 305, 1163, 10.1126/science.1101637

Pao, 2005, Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions, J Clin Oncol, 23, 2556, 10.1200/JCO.2005.07.799

Mitsudomi, 2005, Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence, J Clin Oncol, 23, 2513, 10.1200/JCO.2005.00.992

Tokumo, 2005, The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers, Clin Cancer Res, 11, 1167, 10.1158/1078-0432.1167.11.3

Sauter, 1996, Patterns of epidermal growth factor receptor amplification in malignant gliomas, Am J Pathol, 148, 1047

Kobayashi, 2005, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, N Engl J Med, 352, 786, 10.1056/NEJMoa044238

Pao, 2005, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Med, 2, e73, 10.1371/journal.pmed.0020073

Blagosklonny, 2003, Why Iressa failed: towards novel use of kinase inhibitors, Cancer Biol Ther, 2, 137, 10.4161/cbt.2.2.286

Perez-Soler, 2004, Determinants of sensitivity to the EGFR TK inhibitor erlotinib (E) in a panel of NSCLC cell lines, Proc Am Soc Clin Oncol, 23, 7026, 10.1200/jco.2004.22.90140.7026

Bianco, 2003, Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors, Oncogene, 22, 2812, 10.1038/sj.onc.1206388

Ranson, 2002, ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial, J Clin Oncol, 20, 2240, 10.1200/JCO.2002.10.112

Perez-Soler, 2004, The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer, Clin Cancer Res, 10, 4238s, 10.1158/1078-0432.CCR-040017

Kwak, 2005, Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib, Proc Natl Acad Sci U S A, 102, 7665, 10.1073/pnas.0502860102

Fisher, 2004, A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer, Proc Am Soc Clin Oncol, 23, 3514, 10.1200/jco.2004.22.90140.3514

Wirth, 2004, Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN), Proc Am Soc Clin Oncol, 23, 5540, 10.1200/jco.2004.22.90140.5540

Delord, 2004, A phase Ib dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients, Proc Am Soc Clin Oncol, 23, 3585, 10.1200/jco.2004.22.90140.3585

Mauer, 2004, Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN), Proc Am Soc Clin Oncol, 23, 5539, 10.1200/jco.2004.22.90140.5539

Bozec, 2005, Combined effect of gefitinib (Iressa), with ZD6126, an antivascular drug, and radiotherapy (Rt) on head and neck tumors, an in vivo study, Proc Am Assoc Cancer Res, 46, 2305

Tanaka, 2005, Inhibition of DNA repair in the radiosensitization of NSCLC cells by gefitinib, a specific EGFR-inhibitor, Proc Am Assoc Cancer Res, 46, 1994

Cohen, 2005, FDA drug approval summary: erlotinib (Tarceva®) tablets, The Oncologist, 10, 461, 10.1634/theoncologist.10-7-461

Comis, 2005, The current situation: erlotinib (Tarceva®) and gefitinib (Iressa®) in non-small cell lung cancer, The Oncologist, 10, 467, 10.1634/theoncologist.10-7-467

2005, EMEA: European Medicines Agency; Pre-Authorisation Evaluation of Medicines for Human Use for Tarceva

Taron, 2005, Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas, Clin Cancer Res, 11, 5878, 10.1158/1078-0432.CCR-04-2618